VOOPOO
23.6.2022 18:40:06 CEST | Business Wire | Press release
VOOPOO,a global leading electronic atomization brand, released a seven-day countdown on its official website on June 23rd. According to this, a new product launch themed "More than Infinite" will be held at 10:00 p.m.(GMT+8) on June 29. As the initial new VOOPOO product launch of this year, what will be delivered in the launch is conspicuous.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005539/en/
What stories will be shared in this 8th
Anniversary Show?
The launch event is not only held for new products, but also for celebrating the 8th
establishment anniversary of VOOPOO. Since its establishment, VOOPOO has gained a reputation of developing a variety of revolutionary products. While promoting the development of the industry, VOOPOO achieved leaps of market share year by year. By far, VOOPOO has become a TOP brand in the Open Pod System. VOOPOO has also won a number of Vapoouround 2022 awards
recently, which are known as the Oscars of the atomization industry, and has been highly praised by the industry and users. There is no doubt that VOOPOO will reveal some behind-brand stories at this 8th
anniversary.
Is there a strong association between the Infinity symbol and VOOPOO brand?
The posters released on the official website and social platforms all used the infinity symbol as the main visual element of the launch.VOOPOO has lately launched a number of high-profile events around the world, whether the “Spark Your Life Infinite Challenge ”on the Tik-Tok, or the pop-up events
organized by graffiti artists in the United Kingdom and Indonesia, were all attached to the infinity symbol strongly. Now it is clear that those were organized to warming up the launch. This launch themed as “More than infinity
”, emphasizing that the infinity symbol seems to become the cultural totem of the VOOPOO brand. As for which brand spirit the infinity symbol marks, it will only be revealed on the launch.
What revolutionary breakthroughs will the new products be making in this launch?
Another highlight of the launch is the new products VOOPOO will debut this time. Judging from the relevant content disclosed on the official website, the overall KEY VISION style is very technologically avant-garde, and several products will be released at the same time. For VOOPOO, which was known for its product innovation
, the new products of this time may make various breakthroughs in design and technology as well. The official revealed that the launch will be broadcasting live on its official YouTube channel at 10:00 p.m.(GMT+8) on June 29. At that time, global vape fans and industry observers will witness and participate in this feast served by VOOPOO.
About VOOPOO
VOOPOO is a leading brand of open pod system and has rapidly risen through DRAG products, which have been widely acclaimed globally in a short period of time. VOOPOO focuses on building two core technology platforms [Chip] and [Atomization]. VOOPOO has creatively developed GENE.AI, GENE.TT and other chips. In addition, VOOPOO independently developed three Atomization Platforms, which are TPP,PNP,ITO, aiming at differentiated users. VOOPOO has four major product series - ARGUS, DRAG, VINCI, and V-series(Doric). VOOPOO will continue to develop more national markets in the future, aiming to build one of the most influential global brands.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005539/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
